.Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A02B_DrugsForPepticUlcerAndGastroOesophagealRefluxDis.A02BD17_VonoprazanAndAmoxicillin.VonoprazanAndAmoxicillin .Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A02B_DrugsForPepticUlcerAndGastroOesophagealRefluxDis.A02BD17_VonoprazanAndAmoxicillin.VonoprazanAndAmoxicillin| name: | VonoprazanAndAmoxicillin | |
| ATC code: | A02BD17 | route: | oral |
| compartments: | 1 | |
| dosage: | 20 | mg |
| volume of distribution: | 180 | L |
| clearance: | 10.5 | L/h |
| other parameters in model implementation | ||
Vonoprazan and amoxicillin is a combination therapy used mainly for the eradication of Helicobacter pylori infection. Vonoprazan is a potassium-competitive acid blocker (P-CAB) that inhibits gastric acid secretion, while amoxicillin is a broad-spectrum beta-lactam antibiotic. This combination is clinically approved and used, particularly in Asia, for H. pylori eradication regimens as an alternative to traditional proton pump inhibitor-based therapies.
Pharmacokinetic parameters are estimated based on monotherapy data for vonoprazan and amoxicillin in healthy adult subjects, due to lack of published combined PK model data for fixed-dose or co-administered combination.
Echizen, H (2016). The First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations. Clinical pharmacokinetics 55(4) 409–418. DOI:10.1007/s40262-015-0326-7 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26369775